

In the Claims:

Please cancel claims 6, 8-10, 13-14, 18-19 and 25-26 without prejudice or disclaimer.

This listing of claims will replace all prior versions and prior claim listings in the above-identified application:

1. (currently amended) A method of treating non-insulin dependent diabetes mellitus (NIDDM) in a mammal, comprising administering to the mammal ~~an agent capable of blocking, inhibiting, or ameliorating VEGF-mediated activity such that diabetes is treated, wherein the agent is a VEGF antagonist~~ such that diabetes is treated, wherein the VEGF antagonist is VEGFR1R2-FcΔC1(a).
2. (currently amended) The method of claim 1 wherein the treatment of diabetes results in one or more of decreased serum glucose concentrations, improved glucose tolerance, increased insulin sensitivity, and ~~reduced hyperinsulinemia, and improved glycemic control.~~
- 3 -14. (canceled)
15. (currently amended) A method of improving glucose tolerance or insulin sensitivity in a human subject in need thereof, comprising administering to the subject ~~an agent capable of blocking, inhibiting, or ameliorating VEGF-mediated activity, wherein the agent is a VEGF antagonist~~ such that glucose tolerance or insulin sensitivity is improved, wherein the VEGF antagonist is VEGFR1R2-FcΔC1(a).
- 16-26. (canceled)
27. (new) The method of claim 1, wherein VEGFR1R2-FcΔc1(a) comprises the amino acid sequence of SEQ ID NO:2.
28. (new) The method of claim 27, wherein VEGFR1R2-FcΔc1(a) is encoded by the nucleic acid sequence of SEQ ID NO:1.
29. (new) The method of claim 15, wherein VEGFR1R2-FcΔc1(a) comprises the amino acid sequence of SEQ ID NO:2.

USSN 10/811,170

Office action dated 31 October 2005

Amendment dated 16 December 2005

30. (new) The method of claim 29, wherein VEGFR1R2-Fc Δ c1(a) is encoded by the nucleic acid sequence of SEQ ID NO:1.
31. (new) The method of claim 1, wherein the administering is by injection.
32. (new) The method as claimed in claim 31, wherein the injection is subcutaneous injection.
33. (new) The method as claimed in claim 31, wherein the injection is intravenous injection.
34. (new) The method of claim 15, wherein the administering is by injection.
35. (new) The method as claimed in claim 34, wherein the injection is subcutaneous injection.
36. (new) The method as claimed in claim 34, wherein the injection is intravenous injection.